Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: NATIONAL COMPREHENSIVE CANCER NETWORK · Firm: TARPLIN, DOWNS & YOUNG, LLC
biomarker testing, cost-sharing elimination on breast/prostate, HR1 implementation, fertility preservation
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FRESENIUS MEDICAL CARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
lobbying related to medicare policy, ESRD
Filing targets: Centers For Medicare and Medicaid Services (CMS)
SAS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Source: Senate LDA
| FLAGSHIP PIONEERING |
| 3 |
| 2026 |
| GILEAD SCIENCES, INC. | 3 | 2026 |
| HANSA BIOPHARMA | 3 | 2026 |
| MERCK | 3 | 2026 |
| NATIONAL COMPREHENSIVE CANCER NETWORK | 3 | 2026 |
| NEUROCRINE BIOSCIENCES, INC | 3 | 2026 |
| QUEST DIAGNOSTICS | 3 | 2026 |
| SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | 3 | 2026 |
| SAS | 3 | 2026 |
| FRESENIUS MEDICAL CARE | 1 | 2026 |
| PHREESIA | 1 | 2026 |
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
ISLET Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
ISLET Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Military Next-Gen Collision Avoidance Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Military Next-Gen Collision Avoidance Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Lobbying related to health care technology and program integrity.
Lobbying related to health care technology and program integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
federal budget issues
Lobbying related to pharmaceutical policy and Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
QUEST DIAGNOSTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to diagnostics and Medicare reimbursement policy.
Lobbying related to diagnostics and Medicare reimbursement policy.
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHREESIA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
patient engagement, health care technology
Medicare innovation, patient engagement
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
telehealth, mental health, prescription drug pricing, payment reform
federal budget issues
IRA, prescription drug pricing, payment reform, innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL COMPREHENSIVE CANCER NETWORK via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care coverage and patient access policy.
Lobbying related to health care coverage and patient access policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Federal budget issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
IRA, Medicare and Medicaid payment and coverage issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · 3T
Federal budget issues
Kidney issues, access to innovation, rare disease issues, organ rejection
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues
Federal budget issues
Lobbying related to pharmaceutical, tax, and health care policy
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Medicare & Medicaid coverage and reimbursement issues
Lobbying related to health care policy and research funding
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care policy and research funding
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to domestic pharmaceutical supply
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care policy, access, and coverage
federal budget issues
Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADULT VACCINE ACCESS COALITION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to vaccine and health care policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to disease research, and innovation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical and health care policy
Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues
Federal budget issues
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
IRA, Medicare and Medicaid payment and coverage issues
Federal budget issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care technology and program integrity.
Lobbying related to health care technology and program integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care policy and research funding
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
federal budget issues
Lobbying related to pharmaceutical policy and Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
telehealth, mental health, prescription drug pricing, payment reform
IRA, prescription drug pricing, payment reform, innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Kidney issues, access to innovation, rare disease issues, organ rejection
Federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy
Lobbying related to health care policy, access, and coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL COMPREHENSIVE CANCER NETWORK via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care coverage and patient access policy.
Lobbying related to health care coverage and patient access policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADULT VACCINE ACCESS COALITION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to vaccine and health care policy.
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to domestic pharmaceutical supply
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QUEST DIAGNOSTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to diagnostics and Medicare reimbursement policy.
Lobbying related to diagnostics and Medicare reimbursement policy.
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL COMPREHENSIVE CANCER NETWORK via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Medicare/commercial payment and coverage of cancer services
biomarker testing, cost-sharing elimination on breast/prostate, HR1 implementation, fertility preservation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAS via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
program integrity and technology reform, FDA modernization
IRA, medical review pilot, data use by Medicare Administrative Contractors, program integrity and technology reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization
Medicare & Medicaid payment and coverage issues
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Medicare & Medicaid policy and reimbursement issues, MCED
federal budget issues
IRA, SCREENS for Cancer Act, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
care planning, home and community based care, innovation, NAPA, BOLD Act, Advancing America's Interests Act, ADAPT Act, ASAP Act
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
IRA, innovation, drug pricing in federal programs, orphan drugs, PAPHA reauthorization, competitiveness, supply chain, vaccine access and coverage
Medicare & Medicaid payment and coverage issues
Federal budget issues
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
drug shortages, critical medicines limited to antibiotics and antimicrobials
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Kidney issues, access to innovation, rare disease issues, organ rejection
Federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
IRA, Medicare and Medicaid payment and coverage issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
QUEST DIAGNOSTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
diagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain
physician fee schedule, savings access to lab services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
IRA, supply chain integrity, drug pricing in federal programs, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD
IRA, transparency, vaccines, coverage and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
telehealth, mental health, prescription drug pricing, payment reform
IRA, prescription drug pricing, payment reform, innovation
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ADULT VACCINE ACCESS COALITION via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
Vaccine access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
lobbying related to trade issues
Lobbying related to pharmaceutical and health care policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Lobbying related to pharmaceutical, tax, and health care policy
lobbying related to trade issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
vaccine policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE